New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 5, 2014
07:56 EDTBONEBacterin says study cites potential for OsteoSponge SC
Bacterin International announced that The Journal of Foot & Ankle Surgery has published a study on the "Role of Demineralized Allograft Subchondral Bone in the Treatment of Shoulder Lesions of the Talus: Clinical Results with Two-Year Follow-up." This study followed the use of OsteoSponge SC in the treatment of medial shoulder lesions of the talus, with positive clinical outcomes at 2 years post-op. The OsteoSponge SC procedure has the potential to address defects associated with subchondral bone pathology, which includes failed microfracture procedures and other treatment modalities. The total estimated US market for knee and ankle microfractures in 2014 is approximately 410,000 procedures. Bacterin is the only company in this market with a product specifically positioned to address repair of the subchondral bone in treating these defects, and has demonstrated clinical evidence to support the unique approach.
News For BONE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 14, 2014
07:36 EDTBONEBacterin reports preliminary Q3 revenue $8.4M-$8.5M, consensus $9.15M
Bacterin announced preliminary, unaudited revenue for Q3. The company is expecting total revenue for Q3 to be in the range of $8.4M-$8.5M, representing an increase of 6%-7% when compared to $7.9M reported in 3Q13.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use